Drug profile · INN
lasmiditan
RAYVOW
lasmiditan (RAYVOW) is a serotonin 1f (5-ht1f) receptor agonist. Current US regulatory status: approved.
FDA: approved EMA: approved Nervous system (N02) N02CC08
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — lasmiditan
- US status
- approved
- Class
- Nervous system (N02)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
lasmiditan (RAYVOW) is a serotonin 1f (5-ht1f) receptor agonist. Current US regulatory status: approved.
Key facts
INN lasmiditan
Brand RAYVOW
Mechanism Serotonin 1f (5-HT1f) receptor agonist
Target 5-hydroxytryptamine receptor 1F
Therapeutic class Nervous system (N02)
Formulation TABLET
ATC code N02CC08
Mechanism of action
Serotonin 1f (5-HT1f) receptor agonist
Primary target: 5-hydroxytryptamine receptor 1F
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lasmiditan?
lasmiditan (RAYVOW) is a serotonin 1f (5-ht1f) receptor agonist. Current US regulatory status: approved.
What is the brand name for lasmiditan?
RAYVOW is a marketed brand name for lasmiditan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lasmiditan?
lasmiditan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.